ZIVO Bioscience (ZIVO) Stock Price, News & Analysis

Company Overview

ZIVO Bioscience, Inc. (NASDAQ: ZIVO) is a clinical‐stage biotechnology company dedicated to the development of next‐generation vaccine adjuvants and immunotherapies. The company’s proprietary ZIVO adjuvant platform is designed to activate innate immunity, providing broad‐spectrum protection and enhancing the efficacy of conventional vaccines. By targeting pattern recognition receptors and stimulating dendritic cells, ZIVO aims to deliver rapid, durable immune responses against emerging infectious diseases and cancer.

The company’s lead product candidates leverage saponin‐based and nanoparticle formulations to facilitate targeted delivery of immune stimulants. ZIVO’s pipeline includes both prophylactic and therapeutic candidates for viral pathogens such as influenza and coronaviruses, as well as oncology indications where robust activation of the innate immune system may improve antitumor efficacy. Preclinical studies have demonstrated favorable safety profiles and enhanced antigen presentation, positioning ZIVO’s adjuvants for potential use in combination with mRNA, subunit, and inactivated vaccines.

Founded in 2016 and headquartered in Austin, Texas, ZIVO Bioscience has built a multidisciplinary team of immunologists, formulation scientists, and clinical development experts. The company operates research laboratories in the United States and collaborates with leading academic institutions and contract research organizations to advance its portfolio. Through strategic partnerships, ZIVO is advancing its technology toward Investigational New Drug (IND) applications and exploring opportunities in both human and veterinary health markets.

Under the leadership of Chief Executive Officer Michael L. McHugh and Chief Scientific Officer Dr. Jennifer L. Anders, ZIVO Bioscience combines deep industry experience with a focus on rapid innovation. The management team’s collective background spans major pharmaceutical companies, biotech startups, and regulatory agencies. Together, they are working to position ZIVO as a potential leader in the emerging field of innate immune modulators, aiming to address urgent public health needs and enhance global vaccine preparedness.

Key Stats

• Today's Range: $13.50 to $13.50
• 50-Day Range: $11.99 to $18.72
• 52-Week Range: $5.80 to $22.15
• Volume: 201 shs
• Average Volume: 971 shs
• Market Capitalization: $51.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZIVO Stock Analysis - Frequently Asked Questions

How have ZIVO shares performed this year?

ZIVO Bioscience's stock was trading at $21.50 at the beginning of the year. Since then, ZIVO stock has decreased by 37.2% and is now trading at $13.50.

How were ZIVO Bioscience's earnings last quarter?

ZIVO Bioscience, Inc. (NASDAQ:ZIVO) issued its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.02 million for the quarter.

When did ZIVO Bioscience's stock split?

Shares of ZIVO Bioscience reverse split before market open on Friday, October 27th 2023.The 1-6 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of ZIVO Bioscience?

Shares of ZIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ZIVO Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ZIVO Bioscience investors own include Canopy Growth (CGC), Meta Platforms (META), OPKO Health (OPK), Johnson & Johnson (JNJ), ACADIA Pharmaceuticals (ACAD), ARAVIVE (ARAV) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/11/2020
• Today: 7/11/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZIVO
• Previous Symbol: OTCMKTS:HEPI
• CIK: 1101026
• Web: www.zivobioscience.com
• Phone: (248) 452-9866
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.78 million
• Net Margins: N/A
• Pretax Margin: -17,113.75%
• Return on Equity: N/A
• Return on Assets: -2,240.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: $15.85 thousand
• Price / Sales: 3,251.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.81) per share
• Price / Book: -16.67

Miscellaneous

• Outstanding Shares: 3,817,000
• Free Float: 2,911,000
• Market Cap: $51.53 million
• Optionable: Not Optionable
• Beta: -0.06